Organization: TOPIGEN Pharmaceuticals

TOPIGEN raises $26 million to accelerate clinical trials

Montreal-based TOPIGEN Pharmaceuticals Inc has secured $26 million in series C financing to accelerate Phase II clinical programs related to its lead products for respiratory therapeutics. The total raised to date from all sources is now $75 million and more may be added to the C series. Investors in the latest round are NovaQuest, MMV…